Remote ICD Monitoring Makes The Grade In Two European Studies
This article was originally published in The Gray Sheet
Executive SummaryRemote monitoring of patients with implantable cardioverter defibrillators does not compromise safety and reduces the incidence of inappropriate shocks compared to in-office follow-up, according to two studies from France presented last week at the European Society of Cardiology annual meeting.
You may also be interested in...
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.